Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 33,993,974 $ 11,237,186 $ 65,347,708 $ 21,068,923
General and administrative 8,659,661 5,946,396 26,173,010 18,846,299
Total operating expenses 42,653,635 17,183,582 91,520,718 39,915,222
Loss from operations (42,653,635) (17,183,582) (91,520,718) (39,915,222)
Other (expenses) income:        
Interest/investment income, net 297,648 363,300 1,040,429 1,174,957
Realized loss on short-term investments (336,949) (86,171) (513,328) (244,972)
Unrealized gain (loss) on short-term investments 86,745 3,946 (379,699) 290,973
Total other income - net 47,444 281,075 147,402 1,220,958
Net loss $ (42,606,191) $ (16,902,507) $ (91,373,316) $ (38,694,264)
Loss per common share – basic and diluted (in Dollars per share) $ (2.44) $ (1.05) $ (5.36) $ (2.52)
Weighted average number of common shares outstanding – basic and diluted (in Shares) 17,478,477 16,044,670 17,038,583 15,371,118